TAMPA,
Fla., May 30, 2023 /PRNewswire/ -- PainTEQ, a
fast-growing medical innovation company, announced that on
May 24, 2023, the Patent Trial and
Appeal Board (PTAB) issued a final written decision in an inter
partes review (IPR) proceeding directed to U.S. Patent No.
10,426,539 (539 Patent), handing PainTEQ a decisive victory.
The patent is owned by Orthocision, Inc. and licensed to Omnia
Medical, LLC.
The PTAB determined that all original claims challenged by
PainTEQ, and all amended claims advanced by Orthocision, are
unpatentable over several prior art references. Significantly,
Orthocision failed to advance patentable amended claims directed to
its technology despite having two separate attempts to do so during
the IPR proceeding.
The IPR was prompted when Omnia Medical filed suit in the U.S.
District Court for the Middle District of Florida, alleging that PainTEQ infringed claim
26 of the 539 Patent. The PTAB's ruling demonstrates the
baselessness of this allegation.
"We are very pleased with the PTAB's decision to invalidate all
of the challenged claims of the 539 Patent. This decision shows the
compelling merit of our arguments and our evidence. This is a
significant victory for PainTEQ," said Sean
LaNeve, chief executive officer of PainTEQ.
Documents relating to the IPR can be accessed online at
https://developer.uspto.gov/ptab-web/#/search/documents?proceedingNumber=IPR2022-00335,
which is provided by the U.S. Patent & Trademark Office.
The federal court docket for the federal litigation case is
publicly available on the Public Access to Court Electronic Records
(PACER) website, www.pacer.gov, a website provided by the
Administrative Office of the U.S. Courts.
About PainTEQ: PainTEQ was built to bring
interventional procedures to the market. Working with pain
management specialists to help reduce and eliminate SI joint
dysfunction, PainTEQ's LinQ implant aims to immediately provide
clinical benefits to individuals living with incapacitating lower
back pain through a minimally invasive outpatient procedure.
Learn more at www.painteq.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/painteq-announces-decision-from-patent-trial-and-appeal-board-in-ipr-proceeding-301836774.html
SOURCE PainTEQ